← Back to search
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
CAMBRIDGE, MA, 02138
UnclaimedClaim this profile (free)
Prime contracting experience
17 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Food and Drug Administration | ALP# 125378 - BARDA IDIQ 75A50123D00004 FDA SINGLE AWARD TASK ORDER 75A50123F61003 | 75A50123D00004USAspending | $4,706,084 | Sep 24, 2026 | Sep 24, 2024 – Sep 29, 2027 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | TASK ORDER FOR HUMAN ORGAN CHIP ENABLED DEVELOPMENT OF RADIATION COUNTERMEASURES | 75A50123D00004USAspending | $15,696,867 | Sep 18, 2026 | Sep 28, 2023 – Sep 28, 2028 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | PREFLIGHT PROJECT GOAL IS TO PROVIDE THE REQUIRED PREFLIGHT TESTS TO SUPPORT THE AVATAR FLIGHT PROJECT FOR ITS ARTEMIS II MISSION. | 75A50123D00004USAspending | $3,196,979 | Sep 10, 2026 | Jul 26, 2024 – Sep 30, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | BAA MCMWP #71 "HUMAN ORGAN CHIPS FOR RADIATION COUNTERMEASURE DEVELOPMENT" | — | $7,324,619 | Jun 18, 2026 | Sep 12, 2019 – Mar 15, 2024 |
| Prime | Department of Health and Human Services Food and Drug Administration | UNITED STATES POPULATION LONGITUDINAL DATA AND SPECIALIZED ANALYTIC SUPPORT: RESEARCH ON ENERGY DRINKS/OTHER DIETARY INTAKES/HEALTH OUTCOMES OVER TIME | — | $648,446 | Aug 12, 2025 | Sep 24, 2021 – Sep 29, 2026 |
| Prime | Department of Defense Department of the Army | ER18-1280 FY18 NEW START | — | $1,261,176 | May 7, 2025 | Feb 15, 2019 – Feb 14, 2022 |
| Prime | Department of Defense Defense Health Agency | WRAIR RESEARCH AND DEVELOPMENT. SYSTEMS ENGINEERING ANALYSIS FOR AI/ML PTSD DESIGN OBJECTIVE INDICATOR. | — | $1,026,783 | Mar 17, 2025 | Sep 1, 2022 – Aug 31, 2024 |
| Prime | Department of Defense Defense Advanced Research Projects Agency | LASERS FOR UNIVERSAL MICROSCALE OPTICAL SYSTEMS (LUMOS) WILL BRING EFFICIENT ON-CHIP OPTICAL GAIN TO HIGHLY-CAPABLE INTEGRATED PHOTONICS PLATFORMS AND ENABLE COMPLETE PHOTONICS FUNCTIONALITY ON A SINGLE SUBSTRATE FOR DISRUPTIVE OPTICAL MICROSYSTEMS. | — | $4,708,236 | Dec 5, 2024 | Sep 11, 2020 – Jan 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | HCR FISH DETECTION OF CRYPTIC RNAS | — | $355,153 | May 24, 2024 | Jun 4, 2024 – Jun 3, 2025 |
| Prime | Department of Defense Defense Logistics Agency | DCAA DIRECTOR'S DEVELOPMENT PROGRAM IN LEADERSHIP - ENTREPRENEURSHIP COURSE | SP470320D0008USAspending | $252,289 | Jan 30, 2024 | Mar 10, 2024 – Mar 15, 2024 |
| Prime | Department of Defense Department of the Army | GENERAL FLAG OFFICER SEMINAR AND LEADERSHIP IN HOMELAND SECURITY SEMINAR | W912SV20D0001USAspending | $473,577 | Jan 8, 2024 | Jan 15, 2024 – Dec 31, 2024 |
| Prime | Department of Defense Department of the Army | GENERAL FLAG OFFICER SEMINAR AND LEADERSHIP IN HOMELAND SECURITY SEMINAR | W912SV20D0001USAspending | $459,783 | Jul 26, 2023 | Aug 1, 2023 – Jul 31, 2024 |
| Prime | Department of Transportation Pipeline and Hazardous Materials Safety Administration | IGF::CT::IGF RAPID CLASSIFICATION OF HAZARDOUS MATERIALS IN TRANSPORTATION | — | $435,478 | Jul 19, 2023 | Sep 30, 2017 – Sep 29, 2018 |
| Prime | Department of Defense Department of the Army | THE CONTRACTOR SHALL PROVIDE SEMINAR SERVICES FOR TWO SEMINARS, ONE (1) GENERAL FLAG OFFICER SEMINAR (GFOS) AND ONE (1) LEADERSHIP IN HOMELAND SECURITY (LHS) SEMINAR. | W912SV20D0001USAspending | $459,783 | Mar 16, 2023 | Apr 1, 2023 – Dec 22, 2023 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | HUMAN LYMPHOID FOLLICLE CHIP WITH IN-LINE BIOMARKER SENSING | — | $749,000 | Jan 18, 2023 | Sep 15, 2021 – May 31, 2023 |
| Prime | Department of Defense Department of the Army | THE CONTRACTOR SHALL PROVIDE SEMINAR SERVICES FOR TWO SEMINARS, ONE (1) GENERAL FLAG OFFICER SEMINAR (GFOS) AND ONE (1) LEADERSHIP IN HOMELAND SECURITY (LHS) SEMINAR. | W912SV20D0001USAspending | $446,391 | Aug 25, 2022 | Sep 15, 2022 – Sep 14, 2023 |
| Prime | Department of Defense Department of the Army | THE CONTRACTOR SHALL PROVIDE SEMINAR SERVICES FOR TWO SEMINARS, ONE (1) GENERAL FLAG OFFICER SEMINAR (GFOS) AND ONE (1) LEADERSHIP IN HOMELAND SECURITY (LHS) SEMINAR. | W912SV20D0001USAspending | $446,391 | Aug 1, 2022 | Aug 15, 2022 – Dec 15, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
8 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Energy | RESEARCH & DEVELOPMENT 471853 Parent award context Parent award agency: Department of Energy · Department of Energy Parent award NAICS: 541712 Parent award performance state: NY Parent award description: IGF::OT::IGF TAS::89 0222::TAS M&O CONTRACT FOR BNL View parent award on USAspending | — | $125,700 | Sep 11, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | THE MYERS LAB HAS DEVELOPED PLATFORM TECHNOLOGY FOR THE RAPID CHEMICAL SYNTHESIS OF POTENT INHIBITORS OF THE BACTERIAL LIPOPROTEIN TRANSPORT COMPLEX LOLCDE, WHICH IS SPECIFIC TO AND ESSENTIAL FOR THE GROWTH OF ENTEROBACTERIACEAE, A FAMILY OF GRAM-NEGATIVE BACTERIA. THE BREVITY OF OUR COMPONENT-BASED SYNTHETIC ROUTE, ITS NOTABLE CONVERGENCE, AND THE FACILITY WITH WHICH NEW LEAD MATTER CAN BE DISCOVERED AND SCALED ALL DIFFERENTIATE OUR PROGRAM FROM PRIOR PROGRAMS TO DISCOVER SMALL-MOLECULE INHIBITORS OF LOLCDE. THERE ARE CURRENTLY NO ANTIBIOTICS APPROVED OR IN CLINICAL DEVELOPMENT THAT TARGET LOLCDE, IN SPITE OF MUCH PRIOR EFFORT. WHAT HAS STYMIED ALL PRIOR PROGRAMS TO DEVELOP SMALL-MOLECULE INHIBITORS OF LOLCDE HAS BEEN THE OBSERVED RAPID ACQUISITION OF BACTERIAL RESISTANCE AGAINST ALL PRIOR LEAD MOLECULES, ARISING FROM SINGLE AMINO ACID MODIFICATIONS WITHIN THESE SINGLE-COPY BACTERIAL GENES (LOLC, LOLD, AND LOLE), WITH ATTENDANT MIC SHIFTS OF >16-128-FOLD VS. WILD-TYPE ENTEROBACTERIACEAE. THIS IS NOT THE CASE WITH OUR MOST POTENT INHIBITORS TO DATE. THESE LOLCDE INHIBITORS ARE WELL DIFFERENTIATED FROM ALL PRIOR SMALL-MOLECULE INHIBITORS OF LOLCDE BY THEIR OBSERVED EXTRAORDINARY POTENCIES AGAINST ENTEROBACTERIACEAE, AND, CRUCIALLY, THE FINDING THAT RESISTANCE DEVELOPMENT REQUIRES MULTIPLE CONCURRENT AMINO ACID SUBSTITUTIONS WITHIN THE LOLCDE GENE TARGETS. IT HAS BEEN SUGGESTED AND EXPERIMENTALLY SUPPORTED BY OTHERS THAT LOLCDE-TARGETING ANTIBIOTICS WILL BE LESS HARMFUL TO THE HUMAN MICROBIOTA, WHILE EFFECTIVELY ADDRESSING PATHOGENS SUCH AS E. COLI, K. PNEUMONIA, S. ENTERICA, AND OTHER ENTEROBACTERIACEAE SPP. RESISTANCE MECHANISMS WHICH PASSIVATE OTHER APPROVED GRAM-NEGATIVE ANTIBIOTICS SHOULD NOT IMPEDE OR RECOGNIZE OUR NEW LOLCDE INHIBITORS, AND PRELIMINARY EVIDENCE SUPPORTS THIS CONTENTION. THE LOCATION OF THE TARGET WITHIN THE PERIPLASMIC SPACE OF THE G-NEGATIVE PATHOGEN IS ANOTHER DIFFERENTIATION FROM EXISTING ANTIBIOTICS, WHOSE TARGETS OFTEN LIE WITHIN THE BACTERIAL CYTOPLASM. WITH THE SUPPORT OF CARBX, THIS PROGRAM SEEKS TO PROFILE 6 LOLCDE INHIBITORS THAT WILL BE DIFFERENTIATED AS UNIQUE AMONG GRAM-NEGATIVE FACING ANTIBIOTICS, BECAUSE OF ITS NARROW, BUT HIGHLY IMPORTANT SPECTRUM OF ACTIVITY. IN THIS STAGE, THE PROGRAM WILL EVALUATE THESE COMPOUNDS IN A WELL-DEFINED SET OF ASSAYS TO FURTHER CHARACTERIZE THEIR SAFETY, EFFICACY, AND PHARMACOKINETIC PROPERTIES. THESE CHARACTERIZATIONS WILL ENABLE OUR GROUP TO DIRECT A MEDICINAL CHEMISTRY CAMPAIGN TO ADDRESS ANY LIABILITIES EXHIBITED BY THIS CLASS OF ANTIBACTERIAL AGENTS. KC4183 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $796,464 | Feb 25, 2026 | — – — |
| Subcontractor | National Aeronautics and Space Administration | CARBON-I PHASE A - APPLICATION OF CARBON-I TO QUANTIFY NATIONAL EMISSIONS FROM
COLOMBIA AT 12-KM RESOLUTION S661581 Parent award context Parent award agency: National Aeronautics and Space Administration · National Aeronautics and Space Administration Parent award NAICS: 541715 Parent award performance state: CA Parent award description: THE EARTH SYSTEM EXPLORERS PROGRAM (ESEP) THE CARBON INVESTIGATION (CARBON-I) MISSION PHASE A CONCEPT STUDY. View parent award on USAspending | — | $50,000 | Jun 3, 2025 | — – — |
| Subcontractor | Department of Defense | EVERIFY: DARPA PERSISTENT OCEANOGRAPHIC DEVICE POWER (PODPOWER) Z2208606 Parent award context Parent award agency: Department of Defense · Defense Advanced Research Projects Agency Parent award NAICS: 541714 Parent award performance state: MD Parent award description: BIOLOGICAL UNDERSEA ENERGY PROGRAM (BLUE) View parent award on USAspending | — | $586,362 | Apr 3, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THE MYERS LABORATORY EXTENSIVELY REDESIGNS NATURAL ANTIBIOTIC SCA¿OLDS THEN PREPARES THEM BY CHEMICAL SYNTHESIS TO ACCESS NEW ANTIBIOTICS E¿ECTIVE AGAINST MULTIDRUG-RESISTANT BACTERIAL PATHOGENS. THE STRATEGY PERMITS SCA¿OLD MODI¿CATIONS THAT CANNOT BE ACHIEVED BY SEMI- SYNTHESIS AND PROVIDES A MEANS TO OVERCOME EXISTING CLASS-BASED RESISTANCE MECHANISMS AS WELL AS BROADEN THE SPECTRUM OF ACTIVITY. RECENTLY, EXPLORATIONS TO EXPAND AND REDE¿NE THE LINCOSAMIDE CLASS HAVE DELIVERED A SET OF PARTICULARLY PROMISING LEAD MOLECULES, COLLECTIVELY TERMED THE OXEPANOPROLINAMIDES (OPPS). OPPS OVERCOME RESISTANCE MECHANISMS THAT RENDER >10 OTHER CLASSES OF RIBOSOME-TARGETING ANTIBIOTICS INACTIVE (INCLUDING LINCOSAMIDES, MACROLIDES, AND OXAZOLIDINONES) AND ARE IMPERVIOUS TO RESISTANCE MECHANISMS THAT DISABLE ANTIBIOTICS WITH DI¿ERENT TARGETS (E.G., CELL-WALL BIOSYNTHESIS INHIBITORS, AND GYRASE AND TOPOISOMERASE INHIBITORS). THE LEAD OPPS ARE POTENT, BROAD-SPECTRUM AGENTS, AND DEMONSTRATE IN VIVO E¿CACY AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS. OPPS SHOW EXQUISITE POTENCY IN VITRO AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, AND ENTEROCOCCUS SPP., INCLUDING STRAINS CONSTITUTIVELY EXPRESSING LINCOSAMIDE RESISTANCE DETERMINANTS. OPPS ALSO POTENTLY INHIBIT MANY HIGH-PRIORITY, MDR GRAM-NEGATIVE PATHOGENS IN VITRO INCLUDING NEISSERIA GONORRHOEAE AND ESCHERICHIA COLI. IN VITRO SAFETY PRO¿LING EXPERIMENTS REVEAL THAT OPPS SELECTIVELY INHIBIT BACTERIAL CELL GROWTH AND SUGGEST THAT THEY MAY O¿ER A LARGE THERAPEUTIC WINDOW. WITH THE SUPPORT OF CARB-X, THIS PROGRAM SEEKS TO PRO¿LE FOUR HIGHLY PROMISING LEAD MOLECULES TO ASSESS THEIR POTENTIAL AS LEAD CANDIDATES FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP). THIS PROGRAM WILL EVALUATE THE LEAD OPPS IN A WELL-DE¿NED SET OF ASSAYS TO FURTHER CHARACTERIZE THEIR SAFETY, E¿CACY, AND PHARMACOKINETIC PROPERTIES. THESE CHARACTERIZATIONS WILL ENABLE OUR GROUP TO EITHER PROGRESS ONE OR MORE OPPS CLOSER TO NOMINATION AS A PRE-CLINICAL CANDIDATE OR INFORM FUTURE ANALOG DEVELOPMENT TO ADDRESS ANY LIABILITIES EXHIBITED BY THIS CLASS OF ANTIBACTERIAL AGENTS. 4500004904 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$232,664 | Feb 28, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THE MYERS LABORATORY EXTENSIVELY REDESIGNS NATURAL ANTIBIOTIC SCA¿OLDS THEN PREPARES THEM BY CHEMICAL SYNTHESIS TO ACCESS NEW ANTIBIOTICS E¿ECTIVE AGAINST MULTIDRUG-RESISTANT BACTERIAL PATHOGENS. THE STRATEGY PERMITS SCA¿OLD MODI¿CATIONS THAT CANNOT BE ACHIEVED BY SEMI- SYNTHESIS AND PROVIDES A MEANS TO OVERCOME EXISTING CLASS-BASED RESISTANCE MECHANISMS AS WELL AS BROADEN THE SPECTRUM OF ACTIVITY. RECENTLY, EXPLORATIONS TO EXPAND AND REDE¿NE THE LINCOSAMIDE CLASS HAVE DELIVERED A SET OF PARTICULARLY PROMISING LEAD MOLECULES, COLLECTIVELY TERMED THE OXEPANOPROLINAMIDES (OPPS). OPPS OVERCOME RESISTANCE MECHANISMS THAT RENDER >10 OTHER CLASSES OF RIBOSOME-TARGETING ANTIBIOTICS INACTIVE (INCLUDING LINCOSAMIDES, MACROLIDES, AND OXAZOLIDINONES) AND ARE IMPERVIOUS TO RESISTANCE MECHANISMS THAT DISABLE ANTIBIOTICS WITH DI¿ERENT TARGETS (E.G., CELL-WALL BIOSYNTHESIS INHIBITORS, AND GYRASE AND TOPOISOMERASE INHIBITORS). THE LEAD OPPS ARE POTENT, BROAD-SPECTRUM AGENTS, AND DEMONSTRATE IN VIVO E¿CACY AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS. OPPS SHOW EXQUISITE POTENCY IN VITRO AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, AND ENTEROCOCCUS SPP., INCLUDING STRAINS CONSTITUTIVELY EXPRESSING LINCOSAMIDE RESISTANCE DETERMINANTS. OPPS ALSO POTENTLY INHIBIT MANY HIGH-PRIORITY, MDR GRAM-NEGATIVE PATHOGENS IN VITRO INCLUDING NEISSERIA GONORRHOEAE AND ESCHERICHIA COLI. IN VITRO SAFETY PRO¿LING EXPERIMENTS REVEAL THAT OPPS SELECTIVELY INHIBIT BACTERIAL CELL GROWTH AND SUGGEST THAT THEY MAY O¿ER A LARGE THERAPEUTIC WINDOW. WITH THE SUPPORT OF CARB-X, THIS PROGRAM SEEKS TO PRO¿LE FOUR HIGHLY PROMISING LEAD MOLECULES TO ASSESS THEIR POTENTIAL AS LEAD CANDIDATES FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP). THIS PROGRAM WILL EVALUATE THE LEAD OPPS IN A WELL-DE¿NED SET OF ASSAYS TO FURTHER CHARACTERIZE THEIR SAFETY, E¿CACY, AND PHARMACOKINETIC PROPERTIES. THESE CHARACTERIZATIONS WILL ENABLE OUR GROUP TO EITHER PROGRESS ONE OR MORE OPPS CLOSER TO NOMINATION AS A PRE-CLINICAL CANDIDATE OR INFORM FUTURE ANALOG DEVELOPMENT TO ADDRESS ANY LIABILITIES EXHIBITED BY THIS CLASS OF ANTIBACTERIAL AGENTS. 4500004904 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $716,137 | Jan 19, 2024 | — – — |
| Subcontractor | Department of Defense | SERVICES 4202866979 Parent award context Parent award agency: Department of Defense · Department of the Army Parent award NAICS: 541715 Parent award performance state: MA Parent award description: R&D, SUBCONTRACTOR, & ODCS INVESTIGATING NOISE WITH SCANNING PROBES TO ENHANCE THE COHERENCE OF TRANSOMS View parent award on USAspending | — | $100,000 | Nov 14, 2023 | — – — |
| Subcontractor | Department of Defense | PROCURED GOODS AND/OR SERVICES BETWEEN 01-MAR-23 AND 31-MAR-23 IN SUPPORT OF CONTRACT SOW. P010285370-0 Parent award context Parent award agency: Department of Defense · Department of the Army Parent award NAICS: 541715 Parent award performance state: CA Parent award description: PHASE 1: BASE PERIOD_ View parent award on USAspending | — | $100,000 | Mar 27, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced
- Department of TransportationGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.